KUALA LUMPUR, April 16 (Bernama) -- Prestige BioPharma and Pharmapark LLC have entered into a binding agreement for the exclusive partnership and supply for the commercialisation of Prestige BioPharma's Bevacizumab biosimilar in the Russian Federation.
Prestige's Bevacizumab (HD204) is a mAb biosimilar to Roche’s Avastin®, an inhibitor of vascular endothelial growth factor (VEGF), which is used in combination with other therapies to treat patients with multiple forms of cancer.
According to a statement, HD204 is currently in Phase III clinical development with active recruitment ongoing within the pivotal efficacy and safety trial SAMSON-II.
Positive results were previously reported from the Phase I clinical trial (SAMSON-I) which evaluated the pharmacokinetics, safety and immunogenicity of HD204 to Avastin®.
The partnership arrangement includes the exclusive rights for Pharmapark to commercialise the Bevacizumab biosimilar in the Russian Federation, leveraging the company’s strong sales and marketing capabilities and experience in successfully bringing new biosimilars to market.
Whilst the terms of the deal are not being disclosed, Prestige BioPharma will assume responsibility for product commercial supply out of its manufacturing facilities in Osong, Korea.
Meanwhile, Pharmapark will be responsible for local registration, sales and marketing in the Russian Federation, with the option to manufacture the product in the Federation in line with the Russian import substitution strategy.
This agreement expands upon the existing collaboration between Prestige BioPharma and Pharmapark LLC with the companies signing a licence agreement in July 2019 for Prestige BioPharma’s Herceptin® biosimilar.
More details at https://www.prestigebiopharma.com/
-- BERNAMA
No comments:
Post a Comment